SELLAS Life Sciences Stock (SLS) Slides 18% as a Phase 3 Study Enters Its Evaluation Period
SELLAS Life Sciences stock dropped over 18% on Wednesday alongside a clinical trial update.
Sellas Life Sciences Group Inc. (SLS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 25,000 | $307,750 | -88% | 0% | |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 25,000 | $307,750 | -88% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.59 | 63,400 | $100,806.00 | 104,400 | 2025-11-19 | Filing | |
| $1.48 | 10,000 | $14,800.00 | 20,400 | 2025-06-12 | Filing | |
| $1.69 | 20,000 | $33,800.00 | 30,400 | 2025-05-30 | Filing | |
| $1.80 | 20,000 | $36,000.00 | 41,000 | 2025-05-22 | Filing | |
| $4.94 | 20,000 | $98,742.00 | 23,500 | 2014-02-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.61 | 6,494 | $16,938.30 | 161,689 | 2022-12-05 | Filing | |
| $2.59 | 1,159 | $3,001.81 | 29,347 | 2022-12-05 | Filing | |
| $2.59 | 2,153 | $5,576.27 | 56,344 | 2022-12-05 | Filing | |
| $6.25 | 2,120 | $13,251.91 | 121,167 | 2021-12-02 | Filing | |
| $6.25 | 847 | $5,297.73 | 42,028 | 2021-12-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,367,400 | $16,832,694 | 0.01% | |
| 2. | 1,336,449 | $16,451,691 | 2.85% | |
| 3. | 859,400 | $10,579,214 | 0.01% | |
| 4. | 521,128 | $6,415,090 | 0% | |
| 5. | Imc-chicago, LlcCALL | 385,200 | $4,741,812 | 0% |
News See All
Despite Heavy Hedge Fund Support, Why Sellas Life Sciences (SLS) Fell 16.6% in Q3
Shares of Sellas Life Sciences Group Inc.
Sellas Life (SLS) Falls 13% as Firm Still Mum on ALM Drug Candidate
Sellas Life Sciences (NASDAQ:SLS) saw its share price decline by 13.15 percent on Friday to close at $13.21 apiece, as investors turned increasingly concerned about the company’s silence about its treatment...
SELLAS Life Sciences Stock (SLS) Has a Major Catalyst on the Horizon
SELLAS Life Sciences stock was a hot topic among retail traders on Monday as the company is getting closer to reporting data from its Phase 3 REGAL...
Sellas Life (SLS) Climbs 12% Ahead of 'Potentially Company-Defining' Clinical Trial Result
Sellas Life Sciences bounced back by 12.26 percent on Friday to close at $13.19 apiece, as investors positioned portfolios ahead of a potentially company-defining clinical data release, supported by takeover...
10 Best Performing American Stocks in June 2026
In this article, we will look at the 10 Best Performing American Stocks in June 2026.
10 Stocks Investors Are Chasing Right Now
Ten stocks kicked off the shortened trading week with strong double-digit gains, mirroring a rally in the broader market buoyed by the US and Iran’s decision to end hostilities.
Is SELLAS Life Sciences Group, Inc. (SLS) A Good Stock To Buy Now?
Is SLS a good stock to buy? We came across a bullish thesis on SELLAS Life Sciences Group, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on SLS.
9 Stocks Winning by Double Digits
Nine stocks clocked strong double-digit gains on Thursday, bucking a lackluster performance in the broader market, thanks to stellar earnings performance and acquisition news that sparked buying appetite...
10 Stocks That Will 10X According to Social Media
What started as a pandemic lockdown pastime has become a force Wall Street can't ignore.
Hedge Fund Resource Center